Risk Prediction System for Metabolic Associated Fatty Liver Disease, a Community-based Cohort Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Aged 18 years or older

• Permanent residents in Beijing

• Signing informed consent

Locations
Other Locations
China
Beijing Friendship Hospital, Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Hong You, Doctor
youhong30@sina.com
86-010-63139019
Backup
Xinyu Zhao, Doctor
zhaoxinyujuly@126.com
86-010-63139364
Time Frame
Start Date: 2022-04-18
Estimated Completion Date: 2032-04-18
Participants
Target number of participants: 8103
Sponsors
Collaborators: Chinese Academy of Medical Sciences
Leads: Beijing Friendship Hospital

This content was sourced from clinicaltrials.gov